Melanoma Institute Australia joins forces with Wollongong Wolves in the fight against melanoma
6 February 2017
The world’s largest melanoma-specific treatment and research facility, Melanoma Institute Australia, is joining forces with the Wollongong Wolves Football Club in the battle to reduce Australia’s melanoma rates.
CEO of Melanoma Institute Australia, Carole Renouf, announced the partnership at a function in Wollongong in support of Wolves’ legend David Cervinski who is battling melanoma.
Ms Renouf said the partnership between MIA and the Wollongong Wolves would help promote sun safe behaviour amongst Wolves’ players and also spread the life-saving message to family and fans.
“It is crucial that young Australians take steps now to protect their skin from sun damage,” Ms Renouf said. “Intense, intermittent sun exposure leading to sunburn, especially before puberty, significantly increases your risk of developing melanoma in the future.
“The real tragedy of melanoma is that it is largely preventable, so we are delighted to be working with the Wollongong Wolves from the grass roots level to change behaviour and save lives.”
CEO of Wollongong Wolves Football Club Chris Papakosmas said, “Partnering with Melanoma Institute Australia is one of the most important sponsorships for our club. Following on from David Cervinski’s recent battles we thought this was a great way to raise awareness.”
One Australian dies from melanoma every six hours. Melanoma is the most common cancer affecting 15-39 year-old Australians and the leading cause of cancer death in 20-39 year-olds. The incidence of melanoma in the over 60s is also high, a legacy of sun-damage from decades ago.
As part of the partnership, Melanoma Institute Australia’s logo will feature prominently on the 2017 jerseys of all Wollongong Wolves juniors. There will also be ongoing education, sun-safety and fundraising campaigns, including the Wolves involvement in MIA’s annual Melanoma March fundraising event at Wollongong’s Stuart Park on Sunday 12 March.
“This partnership is crucial in tackling melanoma head on,” said Ms Renouf. “We are delighted to be working with the Wollongong Wolves and together help end melanoma for future generations.”
Wolves’ fans can join the fight against melanoma by participating in Melanoma March Wollongong on Sunday 12 March. To register, go to www.melanomamarch.org.au
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.
Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award.
Mark Whittaker’s ‘Here comes the sun; Defending our summer rays’ (GW 24 Nov) clouds the sun-safe message – which could have disastrous consequences.
Professor Georgina Long is among only 12 researchers from the University of Sydney to be named in the 2018 Highly Cited Researchers List.
‘Wearing sunscreen should be as automatic as wearing a seatbelt. Both are potential life savers.’
The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
A prestigious $10 million Australian Cancer Research Foundation grant has been awarded to ACEMID, an initiative that aims to use 3D total-body imaging and a remote medicine network to improve the detection and diagnosis of early-stage melanoma.
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.